title: Blood pressure 2 years after a chronic disease management intervention study.
abstract: OBJECTIVE
  To follow blood pressure change over time in participants who had participated in a 1- year chronic disease management program focused on blood pressure reduction. The expectation was that blood pressure would return back to the baseline once the study was completed.
  
  
  METHODS
  Prospective, single-arm observational study.
  
  
  METHODS
  Study participants were Status Indians living on-reserve with type 2 diabetes and persistent hypertension who had participated in the DREAM3 study. Blood pressure was measured with the BpTRU automated device every 6 months for 2 years. The primary endpoint was the change in systolic blood pressure over the follow-up period.
  
  
  RESULTS
  Sixty of the original 96 participants agreed to participate in the follow-up. Mean blood pressure at the beginning of the follow-up was 130/76 (SD 18/12) mmHg. Mean blood pressure at the end of the follow-up period was 132/76 (17/9 SD) mmHg. Target blood pressure (<130/80 mmHg) was present in 53%. The 99% confidence limit around change of blood pressure over the 24 months of follow-up was +/-4.7 mmHg.
  
  
  CONCLUSIONS
  Contrary to expectations, the participants maintained their blood pressure control and did not revert to baseline levels. Community awareness and engagement resulting from the chronic disease management program led to a sustainable improvement in the health parameters of the participants and the community that lasted beyond the duration of the 1-year DREAM3 project.
authors.affiliation: Sunnybrook Health Sciences Centre, Toronto, ON, M4N 3M5, Canada. sheldon.tobe@sunnybrook.ca
authors.forename: Sheldon
authors.initials: S
authors.lastname: Tobe
authors.forename: Lloyd
authors.initials: L
authors.lastname: Vincent
authors.forename: Joan
authors.initials: J
authors.lastname: Wentworth
authors.forename: Denise
authors.initials: D
authors.lastname: Hildebrandt
authors.forename: Alexander
authors.initials: A
authors.lastname: Kiss
authors.forename: Nancy
authors.initials: N
authors.lastname: Perkins
authors.forename: Susan
authors.initials: S
authors.lastname: Hartman
authors.forename: Laurie
authors.initials: L
authors.lastname: Ironstand
authors.forename: Jacquie
authors.initials: J
authors.lastname: Hoppe
authors.forename: Katie
authors.initials: K
authors.lastname: Hunter
authors.forename: George
authors.initials: G
authors.lastname: Pylypchuk
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure; D002170:Canada; D002908:Chronic Disease; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000208:ethnology; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000208:ethnology* / Q000503:physiopathology; D007198:Indians, North American; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic
chemical_list: D000959:Antihypertensive Agents